Zemin Xiao

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Jianxing He, Chunxia Su, Wenhua Liang et al. · The Lancet Respiratory Medicine · 2021 · 184 citations

Medicine, Oncology, Pharmacology +13

The lymphocyte-to-monocyte ratio is a superior predictor of overall survival compared to established biomarkers in HCC patients undergoing liver resection

Yuting Yang, Jinghang Jiang, Haojie Yang et al. · Scientific Reports · 2018 · 60 citations · Full text

Medicine, Hematology, Oncology +15

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer

Bolin Chen, Wenxiu Yao, Xingya Li et al. · British Journal of Cancer · 2023 · 38 citations · Full text

Medicine, Oncology, Pharmacology +16

Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study

Jie Xie, Jun Cao, Jingfen Wang et al. · Breast Cancer Research and Treatment · 2017 · 34 citations

Medicine, Oncology, Pharmacotherapy +12

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study

Lingfang Xia, Jing Wang, Chunyan Wang et al. · International Journal of Gynecological Cancer · 2023 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +17